TD Cowen on UroGen Pharma (URGN): 'The Early Launch Is Ramping Nicely & 2026 Should Inflect'
Tweet Send to a Friend
TD Cowen analyst Tara Bancroft reiterated a Buy rating and $35.00 price target on UroGen Pharma (NASDAQ: URGN).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
